STRO · Sutro Biopharma, Inc.

Current Thesis

Sutro Biopharma's remaining recovery case depends on confirmed STRO-006 clinical initiation and a weekly reclaim of the September 4 reference close of $20.07 before a weekly close below $15.34. This is a provisional recovery thesis: the earlier $27 weekly invalidation threshold has already been breached by the September 18 close of $15.34. The original consolidation thesis cannot be carried forward as intact.

The inference remains that the narrative is dead — the September 18, 2026 close confirms further deterioration after the August 12 clinical update, despite the approaching STRO-006 initiation deadline. That describes the failed market narrative, not a conclusion that Sutro's drugs lack activity. The August 12 update placed the next STRO-004 data disclosure in the first half of 2027.

There is a development beyond the September 6 coverage: a public STRO-006 trial listing is now identifiable. However, UC San Diego's listing, marked last updated September 2, pairs a September 14 start date with a status of not yet accepting patients. That combination does not establish first-patient dosing. UC San Diego trial listing

Bullish and bearish views on Sutro Biopharma, Inc.

The model's bull view on Sutro Biopharma, Inc. (STRO), in brief: Clinical preparation has become visible. The bear view: The prior structure has failed. The September 18, 2026 adjusted close of $15.34 is below both the September 4 close of $20.07 and the previously published $27 weekly threshold. These public reference prices establish deterioration, without establishing its cause. Clinical… Both cases follow in full.

Bull Case

• Clinical preparation has become visible. The STRO-006 listing reviewed September 20, 2026 identifies a Phase 1 study and participating institutions. It supports operational preparation, while its recruitment status leaves actual initiation unresolved. UC San Diego trial listing
• Cash supports continued clinical work. Sutro reported $164.3 million in cash, equivalents and marketable securities at June 30, 2026, and on August 12 guided funding into at least the second quarter of 2028. That is management's runway estimate, not a prohibition on further financing. Second-quarter release
• Early activity remains under evaluation. The August 12, 2026 update reported confirmed and ongoing unconfirmed partial responses in STRO-004. Those observations preserve a clinical hypothesis; missing response denominators and limited follow-up prevent a reliable efficacy conclusion. Second-quarter release

Bear Case

• The prior structure has failed. The September 18, 2026 adjusted close of $15.34 is below both the September 4 close of $20.07 and the previously published $27 weekly threshold. These public reference prices establish deterioration, without establishing its cause.
• Clinical efficacy remains unquantified. The August 12, 2026 disclosure covered 49 patients across eight tumour types, with a July 24 data cutoff. Without a response denominator by dose and tumour type, the sample is too small and heterogeneous to support a broad efficacy claim. Second-quarter release
• Financing capacity creates an overhang. The June 2026 registration of an up-to-$100 million at-the-market equity facility established potential share supply. Registration alone does not demonstrate issuance; no updated issuance figure accompanies the September 18 price evidence.

Setup & Price Structure

Measured on September 18, 2026, the shares closed at $15.34, stood 62.5% below the supplied 52-week high of $40.91, and had fallen 51.4% over three months. The 14-period relative strength index (RSI) was 10.8. These supplied adjusted-market observations describe pronounced weakness; they do not establish a reversal.

The September 4 close of $20.07 is the recovery reference, not a demonstrated resistance shelf. Likewise, $15.34 is the latest completed reference close, not established support. The provisional thesis uses a weekly close below that reference as its explicit failure condition because no independently verified lower base is available.

Crowding cannot be measured from this evidence. As of September 18, no dated short-interest, retail-flow or moving-average series is supplied. The price decline and June financing authorization are observable; neither identifies who is selling or proves that the equity facility has been used.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Clinical-initiation deadline. This is the endpoint of the third-quarter STRO-006 initiation guidance reiterated August 12, not an announced presentation date. Confirmed initiation would satisfy the operational part of the recovery case; an explicit delay would break it. Absence of confirmation would leave the deadline unverified rather than prove that dosing did not occur. August company presentation
• ~2027-06-30 — Later clinical window endpoint. The August 12 guidance places the next STRO-004 update in the first half of 2027; this date marks the end of that window, not a scheduled release. Confirmed responses with denominators and longer follow-up are the evidence needed to reassess the clinical narrative. August company presentation

The previously listed September 14–16, 2026 conference window has elapsed. No additional exact company event date was verified for September 20 through October 20.

What Would Change Our Mind

Failure to stabilize around the September 18 reference would end the provisional recovery case: a weekly close below $15.34 is the price invalidation. The earlier $27 condition has already failed and cannot serve as a prospective threshold.

The case would play out only with confirmed STRO-006 initiation within the guided third quarter and a weekly close above the September 4 reference of $20.07 before price invalidation. An explicit postponement beyond September 30 would independently invalidate the operational premise. Confidence remains low because the September 18 price evidence shows deterioration and the available trial listing does not confirm dosing.

Correlation Notes

This is a single-company clinical setup. The September 18 evidence contains no peer-return series or measured correlation supporting a broader biotechnology recovery thesis. Sutro's August 12 clinical schedule supplies the relevant company-specific tests; sector exposure cannot substitute for those disclosures.